Selling Buzz: Amicus Therapeutics Inc. [FOLD] Executive Chairman Crowley John F sells 10,468 shares of the company

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Amicus Therapeutics Inc. shares valued at $111,628 were sold by Crowley John F on Sep 15. At $10.66 per share, Crowley John F sold 10,468 shares. The insider’s holdings dropped to 856,897 shares worth approximately $8.89 million following the completion of this transaction.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Also, Campbell Bradley L sold 5,470 shares, netting a total of over 61,764 in proceeds. Following the sale of shares at $11.29 each, the insider now holds 689,618 shares.

Before that, Quimi Daphne had sold 4,397 shares from its account. In a trade valued at $49,621, the Chief Financial Officer traded Amicus Therapeutics Inc. shares for $11.29 each. Upon closing the transaction, the insider’s holdings decreased to 4,397 shares, worth approximately $3.48 million.

As published in their initiating research note from Morgan Stanley on September 09, 2022, Amicus Therapeutics Inc. [FOLD] has been an Equal-weight and the price target has been revised to $14. This represents a 25.86% premium over Thursday’s closing price. As of January 14, 2022, SVB Leerink has increased its “Mkt perform” rating to a “an Outperform” for FOLD. Earlier on November 15, 2021, Stifel upgraded its rating. Their new recommendation was “a Buy” for FOLD stock which previously was a “a Hold”.

Analyzing FOLD’s Price Performance

On Thursday, Amicus Therapeutics Inc. [NASDAQ: FOLD] plunged -0.29% to $10.38. The stock’s lowest price that day was $10.13, but it reached a high of $10.50 in the same session. During the last five days, there has been a drop of approximately -5.21%. Over the course of the year, Amicus Therapeutics Inc. shares have dropped approximately -10.13%. Shares of the company reached a 52-week high of $12.96 on 08/25/22 and a 52-week low of $5.91 on 05/09/22. A 50-day SMA is recorded $11.25, while a 200-day SMA reached $9.72. Nevertheless, trading volume fell to 1.33 million shares from 1.98 million shares the previous day.

Support And Resistance Levels for Amicus Therapeutics Inc. (FOLD)

According to the 24-hour chart, there is a support level at 10.17, which, if violated, would cause prices to drop to 9.97. In the upper region, resistance lies at 10.54. The next price resistance is at 10.71. RSI (Relative Strength Index) is 40.12 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.41, which suggests the price will decrease in the coming days. Percent R is at 84.87%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Amicus Therapeutics Inc. subject to short interest?

Stocks of Amicus Therapeutics Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -8.18 million shares to 21.75 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 29.93 million shares. A decline of -37.61% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.78 of the overall float, the days-to-cover ratio (short ratio) decline to 5.78.

Which companies own the most shares of Amicus Therapeutics Inc. (FOLD)?

According to Perceptive Advisors LLC filings, the company currently owns 26,895,532 shares, which is about 9.59% of the total FOLD shares outstanding. The investor’s shares have plunged by -660,313 from its previous 13-F filing of 27555845.0 shares. With the completion of the buy transaction, Avoro Capital Advisor LLC’s stake is now worth $300,964,000. The Vanguard Group, Inc. acquire a 0.29% interest valued at $281.4 million while Redmile Group LLC sold a -170,495 stake. A total of 671,648 shares of Amicus Therapeutics Inc. were sold by BlackRock Fund Advisors during the quarter, and 1,157,528 were bought by Janus Henderson Investors US LLC. In its current portfolio, Morgan Stanley & Co. LLC holds 14,936,557 shares valued at $167.74 million.

In terms of Amicus Therapeutics Inc. share price expectations, FactSet research, analysts set an average price target of $14.45 in the next 12 months, up nearly 34.49% from the previous closing price of $10.41. Analysts anticipate Amicus Therapeutics Inc. stock to reach $20.00 by 2022, with the lowest price target being $10.00. In spite of this, 13 analysts ranked Amicus Therapeutics Inc. stock as an Overweight at the end of 2022. On September 30, 2021, JP Morgan assigned a price target of “an Overweight” to the stock and upgraded coverage with a $16.

LEAVE A REPLY

Please enter your comment!
Please enter your name here